NASDAQ:APRI - Apricus Biosciences Stock Price, Price Target & More

$0.2590 0.00 (0.00 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$0.2590
Today's Range$0.25 - $0.2687
52-Week Range$0.25 - $3.34
Volume350,467 shs
Average Volume1.40 million shs
Market Capitalization$6.09 million
P/E Ratio-0.26
Dividend YieldN/A
Beta1.34

About Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences logoApricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. It has a license and stock issuance agreement with Forendo Pharma Ltd. to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. Apricus Biosciences, Inc. operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.

Receive APRI News and Ratings via Email

Sign-up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APRI
CUSIPN/A
Phone858-222-8041

Debt

Debt-to-Equity RatioN/A
Current Ratio4.17%
Quick Ratio4.17%

Price-To-Earnings

Trailing P/E Ratio-0.26
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.76 million
Price / Sales1.05
Cash FlowN/A
Price / CashN/A
Book Value$0.29 per share
Price / Book0.89

Profitability

EPS (Most Recent Fiscal Year)($0.99)
Net Income$320,000.00
Net MarginsN/A
Return on Equity-200.61%
Return on Assets-142.23%

Miscellaneous

Employees11
Outstanding Shares23,440,000

How to Become a New Pot Stock Millionaire

Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions

What is Apricus Biosciences' stock symbol?

Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."

How were Apricus Biosciences' earnings last quarter?

Apricus Biosciences (NASDAQ:APRI) announced its quarterly earnings data on Thursday, March, 1st. The company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.01. During the same quarter in the prior year, the firm earned $0.03 EPS. View Apricus Biosciences' Earnings History.

When is Apricus Biosciences' next earnings date?

Apricus Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Apricus Biosciences.

What price target have analysts set for APRI?

2 brokers have issued twelve-month target prices for Apricus Biosciences' stock. Their forecasts range from $1.00 to $1.00. On average, they expect Apricus Biosciences' share price to reach $1.00 in the next year. View Analyst Ratings for Apricus Biosciences.

Who are some of Apricus Biosciences' key competitors?

Who are Apricus Biosciences' key executives?

Apricus Biosciences' management team includes the folowing people:
  • Mr. Richard W. Pascoe, Chief Exec. Officer, Principal Accounting Officer, Sec. and Director (Age 54)
  • Mr. Brian T. Dorsey, Chief Devel. Officer and Sr. VP (Age 49)
  • Mr. Neil C. Morton, Chief Bus. Officer and Sr. VP (Age 42)
  • Ms. Kelly Deck, Exec. Director of Fin.
  • Ms. Mary Naggs, VP and Gen. Counsel

Has Apricus Biosciences been receiving favorable news coverage?

Press coverage about APRI stock has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Apricus Biosciences earned a coverage optimism score of 0.13 on Accern's scale. They also assigned media headlines about the company an impact score of 47.06 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Apricus Biosciences' major shareholders?

Apricus Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include SARISSA CAPITAL MANAGEMENT LP (13.50%), SABBY MANAGEMENT, LLC (7.68%) and SABBY MANAGEMENT, LLC (7.68%). View Institutional Ownership Trends for Apricus Biosciences.

How do I buy shares of Apricus Biosciences?

Shares of APRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Apricus Biosciences' stock price today?

One share of APRI stock can currently be purchased for approximately $0.2590.

How big of a company is Apricus Biosciences?

Apricus Biosciences has a market capitalization of $6.09 million and generates $5.76 million in revenue each year. The company earns $320,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Apricus Biosciences employs 11 workers across the globe.

How can I contact Apricus Biosciences?

Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-222-8041 or via email at [email protected]


MarketBeat Community Rating for Apricus Biosciences (APRI)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  234
MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe APRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APRI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Apricus Biosciences (NASDAQ:APRI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Apricus Biosciences in the last 12 months. Their average twelve-month price target is $1.00, suggesting that the stock has a possible upside of 286.10%. The high price target for APRI is $1.00 and the low price target for APRI is $1.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.503.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.00$1.00$5.00$4.50
Price Target Upside: 286.10% upside68.65% downside79.86% upside188.46% upside

Apricus Biosciences (NASDAQ:APRI) Consensus Price Target History

Price Target History for Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences (NASDAQ:APRI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018HC WainwrightDowngradeBuy -> Neutral$1.00HighView Rating Details
4/26/2017Rodman & RenshawInitiated CoverageBuy -> BuyLowView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Apricus Biosciences (NASDAQ:APRI) Earnings History and Estimates Chart

Earnings by Quarter for Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences (NASDAQ:APRI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.4 EPS

Apricus Biosciences (NASDAQ APRI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018($0.15)N/AView Earnings Details
3/1/2018Q4 2017($0.15)($0.16)ViewListenView Earnings Details
11/2/2017Q3 2017($0.15)($0.30)ViewN/AView Earnings Details
8/2/2017Q2 2017($0.16)($0.15)ViewListenView Earnings Details
5/11/2017Q1 2017$1.25$1.04$12.00 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.15)($0.04)$3.44 million$0.40 millionViewN/AView Earnings Details
11/8/2016Q316($0.60)($0.19)$1.91 million$4.30 millionViewListenView Earnings Details
8/4/2016Q216($0.08)($0.05)$1.78 million$0.46 millionViewListenView Earnings Details
5/9/2016Q116($0.09)($0.09)$0.83 million$0.63 millionViewN/AView Earnings Details
3/9/2016Q415($0.11)($0.05)$1.81 million$2.60 millionViewListenView Earnings Details
11/5/2015Q315($0.11)($0.10)$1.42 million$1.30 millionViewListenView Earnings Details
8/5/2015Q2($0.13)($0.10)$0.70 million$0.46 millionViewListenView Earnings Details
5/11/2015Q1($0.10)($0.13)$0.95 million$0.48 millionViewListenView Earnings Details
3/16/2015Q4($0.12)($0.09)$0.67 million$1.91 millionViewListenView Earnings Details
11/10/2014Q314($0.09)($0.08)$1.23 million$1.90 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.60)$0.30$2.53 million$5.45 millionViewN/AView Earnings Details
5/12/2014Q114($0.03)($0.09)$2.83 millionViewN/AView Earnings Details
3/17/2014Q212($0.06)($0.04)$2.00 million$0.3620 millionViewN/AView Earnings Details
11/12/2013Q3 2013($1.00)($0.90)$0.90 million$0.03 millionViewN/AView Earnings Details
8/14/2013Q2 2013($1.30)($1.20)$0.50 million$1.19 millionViewN/AView Earnings Details
5/10/2013Q1 2013($1.20)($2.30)$2.50 million$1.02 millionViewN/AView Earnings Details
3/18/2013Q4 2012($2.00)($2.10)ViewN/AView Earnings Details
11/8/2012Q3 2012($1.00)($0.70)ViewN/AView Earnings Details
5/10/2012Q1 2012($1.96)ViewN/AView Earnings Details
3/13/2012Q4 2011($0.20)($2.20)ViewN/AView Earnings Details
11/14/2011Q3 2011($1.10)ViewN/AView Earnings Details
8/15/2011Q2 2011($2.54)ViewN/AView Earnings Details
5/13/2011Q1 2011($1.78)ViewN/AView Earnings Details
3/10/2011Q4 2010($1.78)ViewN/AView Earnings Details
3/31/2010Q4 2009($49.93)ViewN/AView Earnings Details
11/9/2009Q3 2009($1.95)ViewN/AView Earnings Details
8/10/2009Q2 2009($2.55)ViewN/AView Earnings Details
5/11/2009Q1 2009$1.20ViewN/AView Earnings Details
3/16/2009Q4 2008$1.50ViewN/AView Earnings Details
11/10/2008Q3 2008($5.40)ViewN/AView Earnings Details
8/6/2008Q2 2008($3.00)$3.00ViewN/AView Earnings Details
3/12/2008Q4 2007($4.50)($6.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Apricus Biosciences (NASDAQ:APRI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Apricus Biosciences (NASDAQ APRI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.32%
Institutional Ownership Percentage: 12.96%
Insider Trading History for Apricus Biosciences (NASDAQ:APRI)
Institutional Ownership by Quarter for Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences (NASDAQ APRI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/31/2017Alexander J DennerMajor ShareholderBuy6,104$1.63$9,949.52View SEC Filing  
3/3/2016Alexander J DennerMajor ShareholderBuy6,647,728$0.88$5,850,000.64View SEC Filing  
1/12/2016Alexander J DennerMajor ShareholderBuy1,306,819$0.88$1,150,000.72View SEC Filing  
12/29/2014Brian DorseyInsiderBuy10,000$1.05$10,500.00View SEC Filing  
12/22/2014Richard W PascoeCEOBuy10,000$1.02$10,200.00View SEC Filing  
10/23/2014Sandford D SmithDirectorBuy26,500$1.57$41,605.00View SEC Filing  
1/3/2014Leonard A OppenheimDirectorSell15,212$2.49$37,877.88View SEC Filing  
12/26/2013Kleanthis G XanthopoulosDirectorSell17,184$2.55$43,819.20View SEC Filing  
6/21/2013Kleanthis G XanthopoulosDirectorSell2,864$2.52$7,217.28View SEC Filing  
5/23/2013Richard W PascoeCEOBuy35,000$2.85$99,750.00View SEC Filing  
5/23/2013Rusty RayDirectorBuy5,000$2.85$14,250.00View SEC Filing  
5/23/2013Steven Robert MartinCFOBuy20,000$2.85$57,000.00View SEC Filing  
5/21/2013Kleanthis G XanthopoulosDirectorSell2,864$3.36$9,623.04View SEC Filing  
8/20/2012Edward M CoxVPBuy1,500$2.73$4,095.00View SEC Filing  
8/17/2012Rusty RayDirectorBuy4,000$2.81$11,240.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Apricus Biosciences (NASDAQ APRI) News Headlines

Source:
DateHeadline
Apricus Biosciences (APRI) Expected to Announce Earnings of -$0.10 Per ShareApricus Biosciences (APRI) Expected to Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - April 18 at 1:14 AM
Apricus Begins Discussions With Interested Parties For U.S. Vitaros RightsApricus Begins Discussions With Interested Parties For U.S. Vitaros Rights
www.nasdaq.com - April 17 at 5:31 PM
Apricus Bio has work to do before refiling U.S. marketing application for ED cream Vitaros; shares down 10% premarketApricus Bio has work to do before refiling U.S. marketing application for ED cream Vitaros; shares down 10% premarket
seekingalpha.com - April 16 at 5:28 PM
BRIEF-Apricus Biosciences Says Co Received A Nasdaq Staff Deficiency LetterBRIEF-Apricus Biosciences Says Co Received A Nasdaq Staff Deficiency Letter
www.reuters.com - April 16 at 5:28 PM
UPDATE 1-Apricus mulling strategic options after FDA meetingUPDATE 1-Apricus mulling strategic options after FDA meeting
www.reuters.com - April 16 at 9:15 AM
BRIEF-Apricus Biosciences Announces Outcome Of Vitaros™ End-Of-Review Meeting With FDABRIEF-Apricus Biosciences Announces Outcome Of Vitaros™ End-Of-Review Meeting With FDA
www.reuters.com - April 16 at 9:15 AM
FDA asks for new formulation of Apricus erectile dysfunction creamFDA asks for new formulation of Apricus' erectile dysfunction cream
finance.yahoo.com - April 16 at 9:15 AM
Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDAApricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA
finance.yahoo.com - April 16 at 9:15 AM
Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDAApricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA
finance.yahoo.com - April 16 at 9:15 AM
Apricus mulls options; to sell U.S. rights to VitarosApricus mulls options; to sell U.S. rights to Vitaros
finance.yahoo.com - April 16 at 9:15 AM
HC Wainwright Analysts Give Apricus Biosciences (APRI) a $4.00 Price TargetHC Wainwright Analysts Give Apricus Biosciences (APRI) a $4.00 Price Target
www.americanbankingnews.com - April 13 at 7:13 PM
Apricus Biosciences (APRI) Given Buy Rating at HC WainwrightApricus Biosciences (APRI) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - April 9 at 12:44 PM
Apricus Bio closes stock offeringApricus Bio closes stock offering
seekingalpha.com - April 5 at 9:38 AM
Apricus Biosciences Announces Closing of $3.55 Million Public OfferingApricus Biosciences Announces Closing of $3.55 Million Public Offering
finance.yahoo.com - April 4 at 4:35 PM
Global Erectile Dysfunction Market Opportunities 2018: Bayer AG, K. Chemicals, Cristalia Produtos Quimicos Farmaceuticos, Apricus BiosciencesGlobal Erectile Dysfunction Market Opportunities 2018: Bayer AG, K. Chemicals, Cristalia Produtos Quimicos Farmaceuticos, Apricus Biosciences
www.marketwatch.com - April 3 at 8:21 AM
-$0.10 Earnings Per Share Expected for Apricus Biosciences Inc (APRI) This Quarter-$0.10 Earnings Per Share Expected for Apricus Biosciences Inc (APRI) This Quarter
www.americanbankingnews.com - April 1 at 1:21 AM
BRIEF-Sabby Management LLC Reports 7.68 Pct Passive Stake In Apricus BiosciencesBRIEF-Sabby Management LLC Reports 7.68 Pct Passive Stake In Apricus Biosciences
www.reuters.com - March 29 at 5:16 PM
BRIEF-Apricus Biosciences Announces Pricing Of $3.55 Mln Public OfferingBRIEF-Apricus Biosciences Announces Pricing Of $3.55 Mln Public Offering
www.reuters.com - March 29 at 8:24 AM
Edge Therapeutics And Apricus Biosciences Are Moving: Here’s WhyEdge Therapeutics And Apricus Biosciences Are Moving: Here’s Why
finance.yahoo.com - March 29 at 8:24 AM
Apricus Biosciences (APRI) Prices $3.55 Million Public Offering of Common Stock, WarrantsApricus Biosciences (APRI) Prices $3.55 Million Public Offering of Common Stock, Warrants
www.streetinsider.com - March 28 at 5:20 PM
Apricus Biosciences Announces Pricing of $3.55 Million Public OfferingApricus Biosciences Announces Pricing of $3.55 Million Public Offering
finance.yahoo.com - March 28 at 5:20 PM
Apricus Biosciences (APRI) Given a $5.00 Price Target by HC Wainwright AnalystsApricus Biosciences (APRI) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 28 at 2:06 PM
Apricus Biosciences (APRI) Commences Public Offering of Common Stock, WarrantsApricus Biosciences (APRI) Commences Public Offering of Common Stock, Warrants
www.streetinsider.com - March 28 at 8:02 AM
BRIEF-Apricus Biosciences Files For Offering Of 7.1 Mln UnitsBRIEF-Apricus Biosciences Files For Offering Of 7.1 Mln Units
www.reuters.com - March 28 at 8:02 AM
Apricus Biosciences, Inc.: Apricus Biosciences Announces Proposed Public OfferingApricus Biosciences, Inc.: Apricus Biosciences Announces Proposed Public Offering
www.finanznachrichten.de - March 27 at 5:31 PM
Apricus Biosciences Announces Proposed Public OfferingApricus Biosciences Announces Proposed Public Offering
finance.yahoo.com - March 27 at 5:31 PM
Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDAApricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA
finance.yahoo.com - March 26 at 9:12 AM
Apricus Biosciences (APRI) Upgraded to Sell at ValuEngineApricus Biosciences (APRI) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 8:45 PM
BRIEF-Sarissa Capital Management Entered Into Warrant Amendment Agreement With Apricus BiosciencesBRIEF-Sarissa Capital Management Entered Into Warrant Amendment Agreement With Apricus Biosciences
www.reuters.com - March 24 at 5:34 PM
Blog Exposure - Cipher to Acquire Cardiome’s Canadian Business Portfolio for $25.5 Million in CashBlog Exposure - Cipher to Acquire Cardiome’s Canadian Business Portfolio for $25.5 Million in Cash
finance.yahoo.com - March 22 at 8:26 AM
Apricus Biosciences, Vitaros Update, The ED Market, Analysts Target Price, PipelineApricus Biosciences, Vitaros Update, The ED Market, Analysts Target Price, Pipeline
finance.yahoo.com - March 22 at 8:26 AM
Edited Transcript of APRI earnings conference call or presentation 1-Mar-18 9:30pm GMTEdited Transcript of APRI earnings conference call or presentation 1-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 8:48 AM
Apricus Biosciences Inc (APRI) Short Interest Up 115.4% in FebruaryApricus Biosciences Inc (APRI) Short Interest Up 115.4% in February
www.americanbankingnews.com - March 3 at 1:52 AM
Apricus Biosciences (APRI) Releases Quarterly  Earnings Results, Misses Expectations By $0.01 EPSApricus Biosciences (APRI) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - March 2 at 11:56 AM
At $0.9401, Is Apricus Biosciences Inc (NASDAQ:APRI) A Buy?At $0.9401, Is Apricus Biosciences Inc (NASDAQ:APRI) A Buy?
finance.yahoo.com - March 1 at 5:28 PM
Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial ResultsApricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 5:28 PM
Apricus Biosciences, Inc. to Host Earnings CallApricus Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - March 1 at 5:28 PM
Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial ResultsApricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 5:28 PM
Zacks: Analysts Expect Apricus Biosciences Inc (APRI) Will Announce Earnings of -$0.13 Per ShareZacks: Analysts Expect Apricus Biosciences Inc (APRI) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - February 25 at 11:08 PM
Apricus Biosciences (APRI) Scheduled to Post Earnings on ThursdayApricus Biosciences (APRI) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - February 22 at 8:16 PM
Zacks Investment Research Lowers Apricus Biosciences (APRI) to SellZacks Investment Research Lowers Apricus Biosciences (APRI) to Sell
www.americanbankingnews.com - February 22 at 4:32 PM
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call - GlobeNewswire (press release)Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call - GlobeNewswire (press release)
globenewswire.com - February 22 at 8:23 AM
Contrasting Apricus Biosciences (APRI) and Novartis (NVS)Contrasting Apricus Biosciences (APRI) and Novartis (NVS)
www.americanbankingnews.com - February 22 at 5:10 AM
Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in SessionApricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session
www.zacks.com - February 21 at 8:54 AM
Whats Next For Apricus Biosciences Vitaros?What's Next For Apricus Biosciences' Vitaros?
finance.yahoo.com - February 20 at 5:20 PM
Interested In Apricus Biosciences Inc (NASDAQ:APRI)? Here’s What Its Recent Performance Looks LikeInterested In Apricus Biosciences Inc (NASDAQ:APRI)? Here’s What Its Recent Performance Looks Like
finance.yahoo.com - February 19 at 8:28 AM
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™ - GlobeNewswire (press release)Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™ - GlobeNewswire (press release)
globenewswire.com - February 18 at 8:01 AM
Mid-Day Market Update: Dow Rises Over 100 Points; Apricus Biosciences Shares Plummet - BenzingaMid-Day Market Update: Dow Rises Over 100 Points; Apricus Biosciences Shares Plummet - Benzinga
www.benzinga.com - February 18 at 8:01 AM
Shares of Apricus tank after FDA declines to OK erectile dysfunction creamShares of Apricus tank after FDA declines to OK erectile dysfunction cream
www.reuters.com - February 17 at 8:09 AM
Apricus Biosciences (APRI) Receives CRL from FDA for VitarosApricus Biosciences (APRI) Receives CRL from FDA for Vitaros
www.streetinsider.com - February 16 at 5:22 PM

SEC Filings

Apricus Biosciences (NASDAQ:APRI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Apricus Biosciences (NASDAQ:APRI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Apricus Biosciences (NASDAQ APRI) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.